Three patients and two caregivers discuss their experiences with cancer immunotherapy: pembrolizumab (Keytruda) for prostate cancer, CAR T cell therapy for pediatric acute lymphoblastic leukemia, and nivolumab (Opdivo) for glioblastoma. #CRIsummit
Denise Malone, mom and caregiver of the youngest panelist, Cole, stressed the importance of a team approach throughout his treatment. Cole was one of the first pediatric patients to receive CD-19 targeted chimeric antigen receptor (CAR) T cell therapy for acute lymphoblastic leukemia at DFCI. Denise discussed her experience of entering the unknown, advising attendees to trust their doctors, but to also “help them to understand your experience.”
John White, a survivor of metastatic prostate cancer, emphasized the importance of genomic sequencing to find the optimal treatment options for patients based on genetic markers: “Genomic sequencing is the first step. You have to advocate for yourself.”
Ernestina was joined by her daughter, Josileny, on the panel to discuss their experience on a clinical trial combining radiation, chemotherapy, and biweekly infusions of the immunotherapy nivolumab for glioblastoma. When asked about fears going into the trial, Josileny shared that many of their reservations were mitigated by their oncologist, Dr. David Reardon of Dana-Farber Cancer Institute, who addressed their questions and provided support throughout.
Brian Brewer, director of marketing and communications at the Cancer Research Institute, moderated.
The 2019 CRI Immunotherapy Summit in Boston was held at Dana-Farber Cancer Institute on July 27, 2019. Cancer Research Institute Immunotherapy Patient Summits are free half-day Saturday events that provide a forum for patients, caregivers, and advocates to meet together along with scientific and healthcare experts to learn more about how new breakthroughs in immunotherapy are changing standards of care for all cancers. Register at
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to harnessing our immune system’s power to control and potentially cure all cancers. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. Our Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.
Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/